AR076830A1 - Compuestos de carboxamidas de imidazol como moduladores de trpv3 - Google Patents
Compuestos de carboxamidas de imidazol como moduladores de trpv3Info
- Publication number
- AR076830A1 AR076830A1 ARP090104861A ARP090104861A AR076830A1 AR 076830 A1 AR076830 A1 AR 076830A1 AR P090104861 A ARP090104861 A AR P090104861A AR P090104861 A ARP090104861 A AR P090104861A AR 076830 A1 AR076830 A1 AR 076830A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- heteroaryl
- substituted
- cycloalkyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente provee un modulador de receptor vaniloide de potencial transitorio (TRPV) de formula (1). En particular, los compuestos aquí descriptos son utiles para el tratamiento o la prevencion de enfermedades, trastornos y/o desordenes modulados por TRPV3. También se proveen los procesos para preparar los compuestos descriptos, los intermediarios usados en su síntesis, sus composiciones farmacéuticas y métodos para el tratamiento o prevencion de enfermedades, trastornos y/o desordenes modulados por TRPV3. Reivindicacion 1: Un compuesto modulador de receptor vaniloide de potencial transitorio (TRPV) caracterizado por estar representado por la formula (1) en donde el anillo de formula (2) es un anillo heterocíclico o heteroaromático de 5 miembros o 6 miembros que contiene uno o dos enlaces dobles, en los que X y Z son elegidos en forma independiente de -N=, y -C(R1)-; e Y es -O-, -S-, =N-, -N(R1)-, -C(R1)=C(R1)-, o -C(R1)=N-; siendo Y -O-, -S- y -N(R1)- cuando el anillo de formula (2) es un anillo de 5 miembros que contiene un doble enlace; y siendo Y -C(R1)=C(R1)- o -C(R1)=N- cuando el anillo de formula (2) es un anillo de 6 miembros que contiene dos enlaces dobles; R1, que puede ser igual o diferente en cada ocurrencia, es independientemente hidrogeno, halogeno, nitro, ciano, alquilo substituido o no substituido, alquenilo, haloalquilo, alcoxi, cicloalquilo, cicloalquiloxi, arilo, ariloxi, arilalquilo, heterociclo, o heteroarilo; R2, que puede ser igual o diferente en cada ocurrencia, se elige en forma independiente del grupo que consiste en nitro, ciano, halogeno, -OR, alquilo substituido o no substituido, alquenilo, haloalquilo, cianoalquilo, cicloalquilo, arilo, anillo heterocíclico, y heteroarilo; R3 y R4, que pueden ser iguales o diferentes, son cada uno, independientemente, hidrogeno, álcali (incluyendo litio, sodio, o potasio), alquilo substituido o no substituido, haloalquilo, cianoalquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterociclo, -S(O)NR5R6, -S(O)2NR5R6, -S(O)R5 o -S(O)2R5; o R3 y R4, junto con el átomo de nitrogeno al cual están adheridos, pueden formar un anillo cíclico opcionalmente substituido de 4 a 12 miembros; pudiendo el anillo cíclico ser heterociclo o heteroarilo; R se selecciona de hidrogeno, alquilo substituido o no substituido, haloalquilo, cianoalquilo, alquenilo, cicloalquilo, cicloalquilalquilo, alcoxialquilo, arilo, heteroarilo, anillo heterocíclico, arilalquilo, heteroarilalquilo, y heterocicloalquilo; en cada ocurrencia, R5 y R6, que pueden ser iguales o diferentes, son independientemente hidrogeno, alquilo substituido o no substituido, alquenilo, cicloalquilo, cicloalquilalquilo, cicloalquenilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclo, o heterocicloalquilo; y m es un entero comprendido en el rango que va de 0 a 5. ambos inclusive; o su sal farmacéuticamente aceptable.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2610MU2008 | 2008-12-15 | ||
US14113308P | 2008-12-29 | 2008-12-29 | |
IN145MU2009 | 2009-01-22 | ||
US15024809P | 2009-02-05 | 2009-02-05 | |
IN1397MU2009 | 2009-06-10 | ||
US22161509P | 2009-06-30 | 2009-06-30 | |
IN1730MU2009 | 2009-07-29 | ||
US23745609P | 2009-08-27 | 2009-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076830A1 true AR076830A1 (es) | 2011-07-13 |
Family
ID=42241253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104861A AR076830A1 (es) | 2008-12-15 | 2009-12-15 | Compuestos de carboxamidas de imidazol como moduladores de trpv3 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8318928B2 (es) |
EP (1) | EP2367825A1 (es) |
JP (1) | JP2012512151A (es) |
AR (1) | AR076830A1 (es) |
AU (1) | AU2009329192A1 (es) |
CA (1) | CA2746077A1 (es) |
EA (1) | EA201190004A1 (es) |
GE (1) | GEP20146099B (es) |
MX (1) | MX2011006132A (es) |
NZ (1) | NZ595777A (es) |
TW (1) | TW201022283A (es) |
WO (1) | WO2010070452A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2370425A4 (en) * | 2008-12-26 | 2013-02-27 | Glenmark Pharmaceuticals Sa | IMIDAZOLE DERIVATIVES CONDENSED AS TRPV3 ANTAGONISTS |
BR112013003121A2 (pt) * | 2010-08-10 | 2016-06-28 | Abbvie Inc | moduladores de trpv3 |
WO2012072512A1 (en) * | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
DK2686303T3 (en) | 2011-03-18 | 2016-03-29 | Bayer Ip Gmbh | N- (3-carbamoylphenyl) -1 H -pyrazole-5-carboxamide derivatives and their use for controlling animal pests |
WO2012129491A1 (en) | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Trpv3 modulators |
EP2697221A1 (en) | 2011-04-11 | 2014-02-19 | Glaxo Group Limited | N- cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists |
EP2771322A2 (en) | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Novel trpv3 modulators |
AU2013292529A1 (en) * | 2012-07-18 | 2015-02-12 | Marvin J. Miller | 5,5-heteroaromatic anti-infective compounds |
JP7208137B2 (ja) * | 2016-12-09 | 2023-01-18 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物および方法 |
BR112022014933A2 (pt) * | 2020-01-29 | 2022-09-20 | Kamari Pharma Ltd | Compostos e composições para uso no tratamento de distúrbios de pele |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444770A (en) * | 1980-05-29 | 1984-04-24 | Bayer Aktiengesellschaft | New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use |
US5204352A (en) * | 1987-09-29 | 1993-04-20 | The United States Of America As Represented By The Secretary Of The Army | Compounds exhibiting anti-parasitic activity and a method for their use |
GB8820231D0 (en) * | 1988-08-25 | 1988-09-28 | Fujisawa Pharmaceutical Co | New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same |
JPH02105085A (ja) | 1988-10-14 | 1990-04-17 | Komatsu Ltd | 磁気センサ |
JPH07242666A (ja) | 1994-03-08 | 1995-09-19 | Fujisawa Pharmaceut Co Ltd | 複素環化合物 |
AU3053199A (en) * | 1998-04-01 | 1999-10-25 | Ono Pharmaceutical Co. Ltd. | Fused thiophene derivatives and drugs containing the same as the active ingredient |
US20040009537A1 (en) * | 2002-01-11 | 2004-01-15 | Jack Roos | Methods of modulating and of identifying agents that modulate intracellular calcium |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US20060074124A1 (en) * | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
PT1706057E (pt) | 2004-08-18 | 2007-11-09 | Robert Boettcher | Implante dentário intra-ósseo aparafusável |
US7576094B2 (en) | 2004-12-13 | 2009-08-18 | Eli Lilly And Company | Spiro derivatives as lipoxygenase inhibitors |
AP2008004432A0 (en) | 2005-10-07 | 2008-04-30 | Glenmark Pharmaceuticals Sa | Substituted benzofused derivatives and their use as vanilloid receptor ligands |
US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008001115A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
WO2008114006A1 (en) | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
-
2009
- 2009-12-11 US US12/636,213 patent/US8318928B2/en not_active Expired - Fee Related
- 2009-12-14 TW TW098142756A patent/TW201022283A/zh unknown
- 2009-12-15 MX MX2011006132A patent/MX2011006132A/es unknown
- 2009-12-15 AR ARP090104861A patent/AR076830A1/es not_active Application Discontinuation
- 2009-12-15 CA CA2746077A patent/CA2746077A1/en not_active Abandoned
- 2009-12-15 NZ NZ595777A patent/NZ595777A/xx not_active IP Right Cessation
- 2009-12-15 WO PCT/IB2009/007951 patent/WO2010070452A1/en active Application Filing
- 2009-12-15 GE GEAP200912526A patent/GEP20146099B/en unknown
- 2009-12-15 JP JP2011540235A patent/JP2012512151A/ja active Pending
- 2009-12-15 EA EA201190004A patent/EA201190004A1/ru unknown
- 2009-12-15 AU AU2009329192A patent/AU2009329192A1/en not_active Abandoned
- 2009-12-15 EP EP09806128A patent/EP2367825A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20100152192A1 (en) | 2010-06-17 |
EP2367825A1 (en) | 2011-09-28 |
MX2011006132A (es) | 2011-09-01 |
TW201022283A (en) | 2010-06-16 |
WO2010070452A1 (en) | 2010-06-24 |
EA201190004A1 (ru) | 2012-11-30 |
CA2746077A1 (en) | 2010-06-24 |
GEP20146099B (en) | 2014-05-27 |
AU2009329192A2 (en) | 2012-03-29 |
AU2009329192A1 (en) | 2011-12-01 |
NZ595777A (en) | 2013-07-26 |
US8318928B2 (en) | 2012-11-27 |
JP2012512151A (ja) | 2012-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076830A1 (es) | Compuestos de carboxamidas de imidazol como moduladores de trpv3 | |
RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
RU2470918C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ IκB КИНАЗЫ β | |
ES2524045T3 (es) | Nuevas amidas y tioamidas heteroaromáticas como plaguicidas | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
ATE493404T1 (de) | Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR054617A1 (es) | Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden | |
AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
PE20130229A1 (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer | |
AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
AR056211A1 (es) | Derivados de [1,4,6]oxadiazepinas, composiciones farmaceuticas que los contienen en combinacion con otros agentes terapeuticos y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de aspartil-proteasas | |
AR081045A1 (es) | Derivados de quinazolinediona como moduladores trpa1 | |
ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
AR049418A1 (es) | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. | |
AR061264A1 (es) | Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih. | |
AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
EA201390022A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) | |
ATE455113T1 (de) | 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |